Clinical Trials at Wolfe Eye Clinic
Wolfe Eye Clinic has a long history of participation in vision research in areas such as retinal disease, cataract and laser vision correction surgery.
The tradition continues today with our involvement in national studies across multiple disciplines including diabetic eye disease, macular degeneration, glaucoma and pediatric ophthalmology. We believe our research work in these areas will aid better treatment and outcomes for these eye diseases leading to an improved quality of life for many.
Recruiting Clinical Trials
Wet Age-Related Macular Degeneration (AMD):
Study of the Efficacy and Safety of the Port Delivery System with Ranibizumab in Patients with Wet Age-Related Macular Degeneration Previously Treated with Intravitreal Agents Other than Ranibizumab (Belvedere)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04853251
Dry Age-Related Macular Degeneration (Geographic Atrophy):
A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 (HORIZON)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04566445
Study to Evaluate the Safety and Efficacy of Two Doses of GT005 (EXPLORE)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04437368
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Alexion)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT05019521
Diabetic Retinopathy:
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (FOCUS)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03811561
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening (Protocol AF)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04661358
Wet Age-Related Macular Degeneration (AMD), GA and Control samples:
Characterization of aqueous humor and plasma from patients with and without geographic atrophy
Macular Hole:
Vitreous Proteomics in Eyes with a Macular Hole (Protocol AJ)
Recruiting by Invitation
Dry Age Related Macular Degeneration (Geographic Atrophy):
A Study Assessing the Long-Term Safety and Tolerability of RG6147 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAllegOLE)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04607148
Wet Age-Related Macular Degeneration:
Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Wet Age-Related Macular Degeneration (Avonelle-X)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04777201
Diabetic Macular Edema:
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04432831
Active Clinical Trial Studies
Wet Age-Related Macular Degeneration:
Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Wet Age-related Macular Degeneration (Daylight)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04964089
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03823300
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. (DAZZLE)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04049266
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
Learn more here: https://clinicaltrials.gov/show/NCT04005352
Study to Gather Information on Safety and Use of High Dose Aflibercept Injection Into the Eye in Patients With an Age Related Eye Disorder That Causes Blurred Vision or a Blind Spot Due to Abnormal Blood Vessels That Leak Fluid Into the Light Sensitive Lining Inside the Eye (PULSAR)
Learn more here: https://clinicaltrials.gov/show/NCT04423718
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03683251
Retinal Vein Occlusion:
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) (BEACON)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04592419
Diabetic Macular Edema:
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLEAM)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04611152
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04432831
Dry Age-Related Macular Degeneration (Geographic Atrophy):
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (ISEE2008)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04435366
To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) (GTSCOPE)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03894020
First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD (Focus)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03846193
A Study Assessing the Safety, Tolerability, and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) (GALLEGO)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03972709
Upcoming Clinical Trial Studies
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with Wet Age-Related Macular Degeneration (ASCEND)
A Trial Comparing Immediate versus Deferred Surgery for Symptomatic Epiretinal Membranes (Protocol AM)
Completed Clinical Trial Studies
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03622580
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02634333
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03677934
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04503551
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04108156
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03710564
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (DME)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03917472
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD (ALTISSIMO)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03953079
Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03397264
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03038880
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System (RPDS) for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) (LADDER)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02510794
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02713204
A Study of Faricimab (RO6867461) in Participants With Center-involving Diabetic Macular Edema (BOULEVARD)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02699450
A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02686658
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02745119
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02247479
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02247531
A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02424019
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) (TIME-2b)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03197870
A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02307682
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab (FCFD4514S) in Patients With Geographic Atrophy Who Have Completed Genentech-Sponsored Lampalizumab Studies
Learn more here: https://clinicaltrials.gov/ct2/show/NCT01602120